Company research
Cardiol Therapeutics Inc.
CIK 1702123Updated Nov 13, 2026
CRDL price & chart
Loading TradingView…
NASDAQ:CRDL on TradingView ↗About the company
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company's lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular innate immune system response known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · CADSource
Source
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossCAD | -33,818,874Source | -36,677,299Source | -28,128,292Source | -30,930,647Source |
| Additional Financial Items | ||||
| AdjustmentsForDecreaseIncreaseInTradeAccountReceivableCAD | 44,639Source | 42,379Source | 67,178Source | -144,184Source |
| AdjustmentsForSharebasedPaymentsCAD | 10,700,913Source | 14,277,406Source | 4,156,762Source | 5,013,185Source |
| GeneralAndAdministrativeExpenseCAD | 20,297,835Source | 26,264,521Source | 15,561,217Source | 22,373,798Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesCAD | 55,376Source | 41,532Source | 55,376Source | 53,934Source |
| ProceedsFromIssuingSharesCAD | 16,037,974Source | 21,355,588Source | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Additional Financial Items | ||||
| ApplicableTaxRatenumber | 0.27Source | 0.27Source | 0.27Source | 0.27Source |
| BasicEarningsLossPerShareCAD/shares | -0.39Source | -0.51Source | -0.44Source | -0.49Source |
| DilutedEarningsLossPerShareCAD/shares | -0.39Source | -0.51Source | -0.44Source | -0.49Source |
| GeneralAndAdministrativeExpenseCAD | 20,297,835Source | 26,264,521Source | 15,561,217Source | 22,373,798Source |
| ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillCAD | — | — | 0Source | — |
| IncomeTaxExpenseContinuingOperationsCAD | — | — | — | 0Source |
| OtherIncomeCAD | — | 28,223Source | 149,739Source | 164,443Source |
| ProfitLossFromOperatingActivitiesCAD | -34,316,296Source | -40,276,651Source | -29,785,504Source | -41,335,878Source |
| ResearchAndDevelopmentExpenseCAD | 14,018,461Source | 14,012,130Source | 14,224,287Source | 18,962,080Source |
| RevenueFromInterestCAD | 726,401Source | 1,193,342Source | 2,038,465Source | 1,237,632Source |
Filing attachments
tm2629596d1_ex99-1.htm · 6-K · 2026-11-12
Exhibit 99.1 CARDIOL THERAPEUTICS INC. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026 (EXPRESSED IN CANADIAN DOLLARS) (UNAUDITED) Cardiol Therapeutics Inc. Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian Dollars) Unaudited As As at at Sep…
Read attachment ↗tm2629596d1_ex99-2.htm · 6-K · 2026-11-12
Exhibit 99.2 CARDIOL THERAPEUTICS INC. MANAGEMENT'S DISCUSSION AND ANALYSIS THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026 MANAGEMENT’S DISCUSSION AND ANALYSIS Introduction The following management’s discussion and analysis (“MD&A”) of the financial condition and results of the operations of Cardiol Therapeutics Inc. and its subsidiary (the “Corporation” or “Cardiol”) constitutes management of the Corporation's ("Management") review of the factors that affected the Corporation’s financial …
Read attachment ↗tm2628681d1_ex99-1.htm · 6-K · 2026-11-03
Exhibit 99.1 CARDIOL THERAPEUTICS INC. US$75,000,000 OPEN MARKET SALE AGREEMENT SM November 3, 2026 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Cardiol Therapeutics Inc., a corporation organized under the laws of the Province of Ontario, Canada (the “Company”), confirms its agreement (this “Agreement”) with Jefferies LLC (the “Agent”) to issue and sell common shares of the Company (the “Common Shares”) having an aggregate offering price of up to US$75…
Read attachment ↗tm2628681d1_ex99-2.htm · 6-K · 2026-11-03
Exhibit 99.2 Borden Ladner Gervais LLP Bay Adelaide Centre, East Tower 22 Adelaide Street West Toronto, ON, Canada M5H 4E3 T 416.367.6000 F 416.367.6749 blg.com November 3, 2026 Consent of Borden Ladner Gervais LLP We hereby consent to the reference to our name under the headings “Documents Filed as Part of the U.S. Registration Statement” and “Legal Matters,” and to the reference to our name and use of our opinions under the headings “Eligibility for Investment” an…
Read attachment ↗ex991.htm · 6-K · 2026-09-23
EXHIBIT 99.1 Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy Original 110-patient enrollment target achieved ahead of the Company's end-of-September guidance. The MAVERIC Steering Committee recommends expanding enrollment to up to 150 patients to capture sufficient events for a robust assessment of CardiolRx™'s potential to reduce recurrence risk. The recommendation follows a blinde…
Read attachment ↗ex991.htm · 6-K · 2026-09-16
EXHIBIT 99.1 Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds Proceeds strengthen balance sheet ahead of pivotal Phase III MAVERIC trial data readout in recurrent pericarditis and extends cash runway into H1 2028. TORONTO, Sept. 16, 2026 /CNW/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce…
Read attachment ↗